A Growing Microvascular Burden Dr. Amanullah Khan Medical Director sanofi-aventis Pakistan limited.

Slides:



Advertisements
Similar presentations
Adult Medical-Surgical Nursing Endocrine Module: DM Footcare and Patient Teaching Plan.
Advertisements

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.
Foot problems are an important cause of morbidity in diabetes mellitus. vascular and neurologic disease contribute to this problem.
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:
Five cornerstones of the management of the diabetic foot
THE DIABETIC FOOT DR.SEIF I M ELMAHI MD, FRCSI University of Khartoum, Sudan.
DIABETIC FOOT CARE: INVESTING IN PREVENTION IS COST-EFFECTIVE Dr Karel Bakker Chair IDF Consultative Section IWGDF.
1 SCREENING PROCEDURES IN HUMAN MEDICINE EVALUATION OF RESULTS BY MULTIPLE CORRESPONDENCE ANALYSIS Jože Rovan 1, Vilma Urbančič-Rovan 2, Mira Slak 2 1.
Every 30 seconds a lower limb is lost somewhere in the world as a consequence of Diabetes. The Lancet Volume 366 Issue 9498.
JAMES R. CHRISTINA, DPM DIRECTOR SCIENTIFIC AFFAIRS AMERICAN PODIATRIC MEDICAL ASSOCIATION FOOTCARE AND DIABETES.
Epidemiology of Peripheral Vascular Disease Sohail Ahmed School of Population and Health Sciences.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Diabetic Foot: A Surgical Look Mohammed Al-Omran, MD, MSc, FRCSC Assistant Professor & Consultant Vascular Surgery King Saud University.
Al-Fada AA & Bin Abdulrahman KA, King Saud University, Riyadh, Saudi Arabia Assessment of Care for Type 2 Diabetic Patients at the PHC Clinics of a Referral.
Slides current until 2008 Diabetic neuropathy. Curriculum Module III-7C Slide 2 of 37 Slides current until 2008 Diabetic foot disease – the high-risk.
National Diabetes Audit - Foot Examination Keith Hilston – Podiatry Diabetes Lead, May 2013.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Diabetic Foot Infection
Practical Guidelines for the Management of the Diabetic Foot Gerda van Rensburg PODIATRIST Area 556 Johannesburg Hospital.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
In the Name of ALLAH, Ever Beneficent, Infinitely Merciful
Diabetes Mellitus Ibrahim Sales, Pharm.D. Assistant Professor of Clinical Pharmacy King Saud University
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Epidemiology of Diabetes Mellitus by Santi Martini Departemen of Epidemiology Faculty of Public Health University of Airlangga.
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.
Copyright ©2000 BMJ Publishing Group Ltd. Stratton, I. M et al. BMJ 2000; 321:
TREAT TO TARGET IN DIABETES: An Alternative pathway
NHS Medical Directorate Diabetic foot disease Preventing loss of life and limb Dr Rowan Hillson MBE National Clinical Director for Diabetes.
 Diabetes global epidemic  Diabetes related complications far outweigh prevalence rates in Maori  No standardised podiatry assessment in New Zealand.
Pattern of Diabetes Emergencies among adult Yemeni Diabetic Patients Dr. Zayed Atef Faculty of Medicine Sana’a University.
Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients in Thailand Dr. Mya Thandar Dr.PH. Batch 5 1.
Standards of Medical Care for Patients with Diabetes Mellitus John Guzek, MD March 2003.
Management of diabetes mellitus and its complications – comparative study - between a Romanian and a German Diabetes Care Center Author: Feier Ingrid Coordinator:
PREVALENCE OF RISK FACTORS FOR DIABETIC FOOT ULCER AND RISK STRATIFICATION IN TYPE 2 DIABETES DR. NEETA DESHPANDE ASSOCIATE PROF.,JN MEDICAL COLLEGE AND.
Shadi Al-Ahmadi. The Presentation will include: Hypertension Dyslipidemia CVD Type 2 Diabetes-Associated Retinopathy Diabetic Periphral Neuropathy Diabetic.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
PREVELANCE OF COMPLICATIONS OF DIABETES MELLITUS IN EGYPT Prof Morsi Arab University of Alexandria.
Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients Dr. Mya Thandar.
By: Dr. Fatima Makee AL-Hakak University of kerbala College of nursing.
Dr. Abdulraziaq Al-Madani Diabetes Complications in the Gulf Countries.
To assess the prognostic value of variability in home-measured blood pressure (BP) and heart rate (HR) in a general population. Objective: Methods: BP.
Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients in Thailand Dr. Mya Thandar DrPH Batch 5 1.
1 “Diabetic foot” Sensory Autonomic Motor. 2 Neuropathic: 45-60% Purely ischaemic: 10% Mixed neuroischaemic: 25-40% Diabetic foot ulceration.
DIABETES MELLITUS FOOT SYNDROME DR OTUKOYA AO. SR ENDOCRINOLOGY AND METABOLISM UNIT.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
VBWG Growth in heart disease, 2000–2050 Deaths Population Foot DK et al. J Am Coll Cardiol. 2000;35:
Diabetes Mellitus Foot Syndrome Clinical features
Part 3. Diabetes Report Card: HbA 1c Levels in the United States Hoerger TJ, et al. Diabetes Care. 2008;31: Patients (%) HbA 1c (%)
Diabetic Foot. DM largest cause of neuropathy. Foot ulcerations is most common cause of hospital admissions for Diabetics. Expensive to treat, may lead.
Dr. Nadira Mehriban. INTRODUCTION Diabetic retinopathy (DR) is one of the major micro vascular complications of diabetes and most significant cause of.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Cardiac Autonomic Neuropathy in Type 2 Diabetes: Predicting Cardiac Risk Margaret M. McCarthy 1 Lawrence Young 2 Silvio Inzucchi 2 Janice Davey 2 Frans.
Risk Factors for Lower Extremity Ulcer in the Morbidly Obese Diabetics Elly Budiman-Mak MD, MPH, MS. 1,2 Min–Woong Sohn, Ph.D. 1,3 Rodney M. Stuck, DPM.
Diabetes & Diabetic Foot Care Maria M. Buitrago, DPM, MS, FACFAS, FAENS.
Peripheral Artery Disease (PAD)
Regression coefficient (b) RESULTS AND DISCUSSION
Assessment of the diabetic foot; how I assess
Dr John Cox Diabetes in Primary Care Conference Cork
by Dr. Ammar Tlib Al-yassiri
CURRENT TREND OF DIABETIC FOOT SURGERY IN GENERAL HOSPITAL OF KSA: ARE WE DOING ENOUGH TO AVOID AMPUTATIONS? Dr. Anthony Morgan, Dr. Adel Mohammad bin.
The Anglo Scandinavian Cardiac Outcomes Trial
Jagadesh M ,SURYA NARAYANA J, JAYAPRAKASH, NRRAU
Public Health Burden of CAD/PAD
Diabetes: Microvascular Complications and Foot Care
The Clock is ticking for the world’s leaders
Presentation transcript:

A Growing Microvascular Burden Dr. Amanullah Khan Medical Director sanofi-aventis Pakistan limited

Overview: Diabetes in Pakistan Pakistan among top 10 nations for harboring diabetics. 1 Prevalence of T2DM in Pakistan is high to 11% mio. people with diabetes are between years (IDF-2012) 1 Pakistan will have 13.9 mio. diabetics by 2020, making it the 4th most populous country with diabetic patients 2 1-Diabetes Atlas- IDF Wild S. Diabetes Care 27:1047–1053, 2004

3 Harris MI. Clin Invest Med 1995;18:231–239; Nelson RG et al. Adv Nephrol Necker Hosp 1995;24:145–156; WHO. 2002;Fact Sheet N° 138. Microvascular Complications Macrovascular Complications Diabetic Retinopathy Leading cause of blindness in working-age adults Diabetic Nephropathy Leading cause of end-stage renal disease Heart Disease Leading cause of mortality in patients with Type 2 diabetes Peripheral Vascular Disease Leading cause of non-traumatic lower-extremity amputations Diabetic Neuropathy Leading cause of diabetic foot syndrome and non-traumatic lower-extremity amputations Stroke 25% of all ischemic strokes are due to diabetes alone or with hypertension Association of Diabetes Mellitus with Micro & Macrovascular Complications Endocrinol Metab Clin 1996;25: (DCC Trial) Risk of complications and HbA1c HbA1c (%) Relative risk in % Retinopathy Nephropathy Microalbuminuria Neuropathy

Epidemiology of Diabetic Foot Syndrome (DFS) DFS encompasses multiple pathologies, including diabetic neuropathy peripheral vascular disease Charcot neuroarthropathy foot ulceration osteomyelitis and the potentially preventable endpoint, amputation 1 Lifetime risk of a person with diabetes developing a foot ulcer is 25% 2 Studies from Pakistan show 1 prevalence of diabetic foot ulceration - 4 to 10% & amputation rate following foot ulceration - 8 to 21% Scant and isolated data available on DFS in Type-2 diabetics of Pakistan 1. Basit A, Hydrie ZI, Rubina Ahmedani MYH, Masood Q. J Coll Physicians Surg Pak 2004; 14(2) Ince P, Abbas ZG, Lutale JK, et al. Diabetes Care 2008;31:964–967

is the first large study designed to estimate the burden of DFS in T2DM patients attending General Practitioner’s clinics August March 2011

Investigators Hyderabad: Amir Saleem But Merajuddin Nizami Sialkot: Qamar Hameed Qurieshi Lahore: Asif Mahmood Qadri Bakhtawer Ali Syed Manzoor-ul-Haq Saeed Ahmed Sohail Ahmed Zafar Iqbal Bhatti Gujrat Abdul Sattar Major Sarfaraz 08 cities across Pakistan 25 investigators nationwide Karachi: Khalid Farooq Ramiz Ali Riasat.A. Khan Shakir Hussain Shahid Akhtar Tajwer Anees V.M Lohana Multan Saeed Ahmed Safder Khan Zaheer Abbas Faisalabad Altaf-ur-rehman Azeem Imtiaz Jami Muhammad Arif Gujranwala: Mohammad Shafique

Study Objectives Primary: To estimate the prevalence of DFS in established T2DM patients Secondary: To document patient profile of and categorize them according to risk classification To determine the HbA1C levels

Study Duration & Patient Recruitment –Overall study duration: 7 months (Aug 10 - Mar 11) –Recruitment period: 1 month per investigator –Patient recruitment: 10 consecutive T2DM patients per investigator Age > 18 years Male and Female patients Given written informed consent

Definition of DFS A patient suffering from DFS is defined as a person with current ulcer or/and gangrene or/and healed ulcer or/and lower limb amputation

Risk-Classification of Diabetes Foot complications CategoryRisk Profile 0Sensation intact 1 Diminished sensation Blood supply intact no foot deformities such as hammer or claw toes 2 Diminished sensation Blood supply compromised or foot deformity such as hammer or claw toes 3Previous ulcer or amputation (Screening for the diabetic foot – How & Why; International Working Group on the Diabetic Foot)

Characteristics of All Patients at Consultation Characteristics (n=230) Age yrs (mean + S.D)53.8 ± 9.9 Male40.9% Female59.1% BMI (mean + S.D)29 ± 5 BP Systolic mmHg (mean + S.D) ± 18.9 BP Diastolic mmHg (mean + S.D)86.2 ± 10.2 Duration of Diabetes yrs (mean + S.D)7.9 ± 5.5 Current FBS mg/dL (mean + S.D) ± 60.2 Current HbA1c (%) (mean + S.D) 8.8 ± 2.0

The most common findings observed on foot examination were –dryness of skin 39.6% (91/230) –cracked skin 30.9% (71/230) –discoloration/pigmentation 15.7% (36/230) 8.7% (20/230) had a foot ulcer at the time of examination Six percent had history of previous foot ulcer Results – Foot Examination

Ankle Brachial Pressure Index: ABPI On ABPI assessment 41% (94/230) patients had impaired values (< 0.9) Mean ABPI (± 0.13) Mean ABPI (± 0.13) L R

Categorization of patients based on international consensus on diabetic foot risk classification Risk Categories N=230

Endocrinol Metab Clin 1996;25: (DCC Trial) RR Patients (%) n= 32 HbA1c Distribution in DFS Patients N= 230 HbA1c Distribution (All Patients) & Risk of DFS

DFS Prevalence The prevalence of DFS in this population was (C.I 10.0%-18.9%) 13.9% There were 32 patients with manifestation of DFS 198 patients with normal feet Extreme findings N=230 % Previous Hx. of diabetic foot ulcer156.5 Current ulceration208.7 Amputation31.3 Gangrene10.4

Conclusions Prevalence of DFS was 13.9 % in a relatively young population (mean age 54 years) One third (75/230) patients were at high risk of DFS based on ADA risk classification Extreme degree of foot complication (category 3) which includes ulcers and amputation was found in 13.9% DFS is prevalent across all HbA1c levels. Data indicates that these patients have poor glycaemic control (mean HbA1c 9.4%) Foot examination is essential to identify DFS

Thank you

BACKUP

Conclusion Prevalence of DFS was 13.9 % in a relatively young population (mean age 54 years) One third (75/230) of the patients were at high risk of DFS based on ADA risk classification Extreme degree of foot complication (category 3) which includes ulcers and amputation was found in 13.9% DFS is prevalent across all HbA1c levels Data indicates that these patients have poor glycaemic control (mean HbA1c 9.4%) Patients with DFS were more likely to be past smokers with a history of CAD and stroke Prescribed treatment for patients with DFS was not different from those with normal feet

Conclusion The current burden is further aggravated by the high proportion of population at risk of DFS, a significant minority of which is prone to high risk of “extreme degree of foot infections The association of poor knowledge about DFS with poor foot care has already been noted, but a point of further concern is the low rate of prescription of insulin in patients with DFS in Pakistan This implies low awareness of appropriate treatment options even in healthcare providers dealing with patients’ routine care Considering the poor glycemic control, associated risk factors of DFS and existing treatment in the population, there’s a need for early diagnosis and optimization of treatment for the management of not only diabetes but also foot complications in this population

Associated Risk Factors of All Patients at Consultation Associated Risk Factors n (%) Current Smoker Past Smoker Hypertension Nephropathy Coronary Artery Disease Peripheral Artery Disease104.3 Stroke104.3

Background Diabetic Treatment of All Patients at Consultation Treatment n % OADs Metformin Sulphonylurea Alpha Glucosidase Inhibitor 93.9 TZDs Monotherapy Two OADs > Two OADs Insulin 7934% Both %

Treatment N = 202 n=4 n=29 n=163 Percentage (%) Therapy

Findings on assessment for DFS in diabetic patients (N=230) Parametersn(%) Physical examination of feet Dryness of skin Cracked skin Discoloration/Pigmentation Ingrown toe nails Infection Callus219.1 Blister135.7 Muscle wasting229.6 Neurological Assessment Sensation absent on monofilament examination Pinprick sensation absent Ankle reflexes absent Vibration absent3716.5

Three most common associated risk factors reported by patients in both the groups Hypertension 55.7% (128/230) Past Hx of smoking 19.6% (45/230) Coronary Artery Disease 19.6% (45/230)

Parametersn(%) Vascular Assessment Varied temperature gradient Foot pulses (by palpation) absent Impaired ABPI (<0.9) Extreme findings Previous Hx. of diabetic foot ulcer156.5 Current ulceration208.7 Amputation31.3 Gangrene10.4 Deformity114.8 Findings on assessment for DFS in diabetic patients (N=230)

Associated Risk Factors in Both Groups * signifies statistically significant difference, p <0.05.

HbA1c levels (%)n (%)Odds ratiop value <76 (18.8) – 8.03 (9.4) – 9.04 (12.5) – (18.8) >1013 (40.6) Distribution of patients with DFS across HbA1c levels (N=32) Reference category for Odds Ratio, HbA1c <7.0%

Comparison of treatment between patients with diabetic foot syndrome & normal feet TreatmentDFS (n=32)Normal feet (n=198) OADs only19 (59.4)129 (65.2) Monotherapy4 (21.1)27 (20.9) Two OADs12(63.2)81 (62.8) >2 OADs3 (15.8)21 (16.3) Insulin only0 (0.0)7 (3.5) OADs + insulin13 (40.6)59 (29.8)

The ABPI is the ratio of the blood pressure in the lower legs to the blood pressure in the arms. Compared to the arm, lower blood pressure in the leg is a symptom of blocked arteries (peripheral vascular disease) ABPI calculation: –Divide ankle systolic blood pressure by brachial artery systolic blood pressure. –An ABPI >0.9 is normal <0.8 is associated with claudication <0.4 is commonly associated with ischemic rest pain and tissue necrosis. ABPI= Ankle systolic blood pressure Brachial systolic pressure Ankle Brachial Pressure Index: ABPI